OverviewSuggest Edit

Aura Biosciences is a clinical-stage biotechnology company that designs an oncology platform for the delivery of drugs targeting cancer indications, focusing on ocular and urologic oncology. Its NanoSmart drug delivery system encapsulates therapies within protein nanoparticles. The company also develops virus-like drug conjugates (VDCs) such as AU-011 for the first-line treatment of primary choroidal melanoma.
TypePublic
Founded2009
HQCambridge, MA, US
Websiteaurabiosciences.com
Overall CultureA+

Recent NewsAll News

Latest Updates

Employees (est.) (Oct 2021)42
Share Price (Dec 2021)$17(+3%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Aura Biosciences

Elisabet de los Pinos

Elisabet de los Pinos

Chief Executive Officer, Director
Mark de Rosch

Mark de Rosch

Chief Operating Officer
Julie Feder

Julie Feder

Chief Financial Officer
Cadmus Rich

Cadmus Rich

Chief Medical Officer and Head of Research and Development
Abhijit Narvekar

Abhijit Narvekar

Executive Medical Director, Clinical Development and Medical Affairs
David Johnson

David Johnson

Chairman
Show more

Aura Biosciences Office Locations

Aura Biosciences has an office in Cambridge
Cambridge, MA, US (HQ)
85 Bolton St
Show all (1)

Aura Biosciences Financials and Metrics

Aura Biosciences Revenue

Market capitalization (31-Dec-2021)

485.5m

Closing stock price (31-Dec-2021)

17.0
Aura Biosciences's current market capitalization is $485.5 m.
Show all financial metrics

Aura Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Aura Biosciences Online and Social Media Presence

Embed Graph

Aura Biosciences Company Culture

  • Overall Culture

    A+

    94/100

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Aura Biosciences News and Updates

Aura Biosciences takes in $30 mln Series C

Cambridge, Massachusetts-based Aura Biosciences, a biotechnology company, has raised $30 million in Series C financing. Lundbeckfonden Ventures and Arix Bioscience plc led the round with participation from other investors that included Advent Life Sciences, Chiesi Ventures, Ysios Capital, Alexandria…

Aura Biosciences Blogs

Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights

Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights Content Import Wed, 11/24/2021 - 16:06 Aura Biosciences Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights …

Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 23, 2021-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications including ocular and urologic cancers, today announced that

Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology 2021 Annual Meeting

Presentations Include Final Safety and Efficacy Data from the Phase 1b/2 Trial using Intravitreal Administration and Updated Safety Data from the Phase 2 Trial using Suprachoroidal Administration CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 15, 2021-- Aura Biosciences , a clinical-stage oncology

FDA Grants Orphan Drug Designation to Aura Biosciences’ Novel Treatment for Uveal Melanoma

FDA Grants Orphan Drug Designation to Aura Biosciences’ Novel Treatment for Uveal Melanoma kannan.parames… Fri, 10/15/2021 - 08:54 FDA Grants Orphan Drug Designation to Aura Biosciences’ Novel Treatment for Uveal Melanoma May 21, 2015 This release is a backfi…

Aura Biosciences Announces Publication Describing Selective Binding of Viral-like Particles to Cancer Cells

Aura Biosciences Announces Publication Describing Selective Binding of Viral-like Particles to Cancer Cells kannan.parames… Fri, 10/15/2021 - 08:54 Aura Biosciences Announces Publication Describing Selective Binding of Viral-like Particles to Cancer Cells September 21, 2015 …

Aura Biosciences Forms Clinical Advisory Board in Ocular Oncology and Strengthens Clinical Team to Prepare for Clinical Development of Lead Program in Ocular Melanoma

Aura Biosciences Forms Clinical Advisory Board in Ocular Oncology and Strengthens Clinical Team to Prepare for Clinical Development of Lead Program in Ocular Melanoma kannan.parames… Fri, 10/15/2021 - 08:53 Aura Biosciences Forms Clinical Advisory Board in Ocular Oncology and Strengthens C…
Show more

Aura Biosciences Frequently Asked Questions

  • When was Aura Biosciences founded?

    Aura Biosciences was founded in 2009.

  • Who are Aura Biosciences key executives?

    Aura Biosciences's key executives are Elisabet de los Pinos, Mark de Rosch and Julie Feder.

  • How many employees does Aura Biosciences have?

    Aura Biosciences has 42 employees.

  • Who are Aura Biosciences competitors?

    Competitors of Aura Biosciences include L.E.A.F. Pharmaceuticals, IDAC Theranostics and Phenex Pharmaceuticals.

  • Where is Aura Biosciences headquarters?

    Aura Biosciences headquarters is located at 85 Bolton St, Cambridge.

  • Where are Aura Biosciences offices?

    Aura Biosciences has an office in Cambridge.

  • How many offices does Aura Biosciences have?

    Aura Biosciences has 1 office.